Drug prices: Expensive, but for whom?

The Medicare Drug Price Negotiation Program selects drugs for price talks based on the highest level of gross covered costs to Medicare, not to beneficiaries. What does that mean? Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research, explains how costs add up for drugs that may be relatively inexpensive, but that are used by a large number of beneficiaries. That is a different calculation than drugs that cause sticker shock at the pharmacy counter.